Skip to main content

Compare use cases

Drop two or three slugs into the URL — for example ?slugs=demo-mia-breast-screening,demo-idx-dr-retinopathy — or pick from the validated catalogue below.

Pick from validated:

Clear selection
Type-2 diabetes long-term outcome predictor

Netherlands

AI second reader for breast cancer screening

United Kingdom

Autonomous diabetic retinopathy screening in primary care

Netherlands

Trust badgeValidatedValidatedValidated
Evidence strengthRobust evidenceEmerging evidenceRobust evidence
Pipeline stageValidatedValidatedValidated
Intended useEstimates 5-year risk of major diabetes-related complications (cardiovascular, renal, retinal) from longitudinal primary-care records to support care-plan intensification.Acts as an independent second reader of screening mammograms to support the double-reading workflow and reduce reader workload without lowering cancer detection.Provides an autonomous screening decision for more-than-mild diabetic retinopathy from retinal fundus images, referring positive cases to ophthalmology.
SpecialtyEndocrinologyRadiologyOther
AutonomyInforms a human (advisory)Informs a human (advisory)Autonomous (acts without a human)
DeploymentActive deploymentActive deploymentActive deployment
EU AI Act tierHigh-riskHigh-riskHigh-risk
EU MDR classNot a deviceClass IIbClass IIb
CE markingNot requiredCE markedCE marked
NICE ESF tierTier C — treat / diagnose / calculate riskTier C — treat / diagnose / calculate riskTier C — treat / diagnose / calculate risk
Headline metricAUC / AUROC: 0.82Sensitivity: 0.91Sensitivity: 0.87
Subgroup assessedYesYesYes